Presently, there are certain limitations to monoclonal antibody therapy, including the absence of sensitive predictive biomarkers for clinical application, a low overall patient response rate to antibody therapy, the inadequacy of existing efficacy assessment indicators for objective evaluation, and the manifestation of potent adverse effects associated with tumor immunotherapy.[82] Small‐molecule inhibitors are considered promising alternative strategies because they can traverse cellular membranes and directly modulate the PD‐1/PD‐L1 signaling pathway. This evidence concerns the gene CD274 and neoplasm.